Natural product derived antiprotozoal agents: synthesis, biological evaluation, and structure-activity relationships of novel chromene and chromane derivatives. 2013

Dipak Harel, and Dirk Schepmann, and Helge Prinz, and Reto Brun, and Thomas J Schmidt, and Bernhard Wünsch
Institut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhelms-Universität Münster , Corrensstraße 48, D-48149 Münster, Germany.

Various natural products with the chromane and chromene scaffold exhibit high antiprotozoal activity. The natural product encecalin (7) served as key intermediate for the synthesis of different ethers 9, amides 11, and amines 12. The chromane analogues 14 and the phenols 15 were obtained by reductive amination of ketones 13 and 6, respectively. Angelate 3, ethers 9, and amides 11 did not show considerable antiprotozoal activity. However, the chromene and chromane derived amines 12, 14, and 15 revealed promising antiprotozoal activity and represent novel lead compounds. Whereas benzylamine 12a and α-methylbenzylamine 12g were active against P. falciparum with IC50 values in the range of chloroquine, the analogous phenols 15a and 15b were unexpectedly 10- to 25-fold more potent than chloroquine with selectivity indexes of 6760 and 1818, respectively. The phenylbutylamine 14d based on the chromane scaffold has promising activity against T. brucei rhodesiense and L. donovani.

UI MeSH Term Description Entries
D002839 Chromans Benzopyrans saturated in the 2 and 3 positions. Dihydrobenzopyrans
D000981 Antiprotozoal Agents Substances that are destructive to protozoans. Schizonticides,Agents, Antiprotozoal
D001688 Biological Products Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay. Biologic,Biologic Drug,Biologic Product,Biological,Biological Drug,Biological Medicine,Biological Product,Biologics,Biopharmaceutical,Natural Product,Natural Products,Biologic Drugs,Biologic Medicines,Biologic Pharmaceuticals,Biologic Products,Biological Drugs,Biological Medicines,Biologicals,Biopharmaceuticals,Products, Biological,Drug, Biologic,Drug, Biological,Drugs, Biologic,Drugs, Biological,Medicine, Biological,Medicines, Biologic,Medicines, Biological,Pharmaceuticals, Biologic,Product, Biologic,Product, Biological,Product, Natural
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D060326 Chemistry Techniques, Synthetic Methods used for the chemical synthesis of compounds. Included under this heading are laboratory methods used to synthesize a variety of chemicals and drugs. Inorganic Synthesis,Inorganic Synthesis Methods,Inorganic Synthesis Techniques,Methods of Inorganic Synthesis,Methods of Organic Synthesis,Methods of Peptide Synthesis,Organic Synthesis,Organic Synthesis Methods,Organic Synthesis Techniques,Peptide Synthesis Methods,Peptide Synthesis Techniques,Peptide Synthesis, Synthetic,Synthetic Chemistry Techniques,Synthetic Peptide Synthesis,Chemistry Technique, Synthetic,Inorganic Syntheses,Inorganic Synthesis Method,Inorganic Synthesis Technique,Method, Inorganic Synthesis,Method, Organic Synthesis,Method, Peptide Synthesis,Methods, Inorganic Synthesis,Methods, Organic Synthesis,Methods, Peptide Synthesis,Organic Syntheses,Organic Synthesis Technique,Peptide Syntheses, Synthetic,Peptide Synthesis Method,Peptide Synthesis Technique,Syntheses, Inorganic,Syntheses, Organic,Syntheses, Synthetic Peptide,Synthesis Method, Inorganic,Synthesis Method, Peptide,Synthesis Methods, Inorganic,Synthesis Methods, Peptide,Synthesis Technique, Inorganic,Synthesis Technique, Organic,Synthesis Technique, Peptide,Synthesis Techniques, Inorganic,Synthesis Techniques, Organic,Synthesis Techniques, Peptide,Synthesis, Inorganic,Synthesis, Organic,Synthesis, Synthetic Peptide,Synthetic Chemistry Technique,Synthetic Peptide Syntheses,Technique, Inorganic Synthesis,Technique, Organic Synthesis,Technique, Peptide Synthesis,Technique, Synthetic Chemistry,Techniques, Inorganic Synthesis,Techniques, Organic Synthesis,Techniques, Peptide Synthesis,Techniques, Synthetic Chemistry
D020128 Inhibitory Concentration 50 The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture. IC50,Concentration 50, Inhibitory

Related Publications

Dipak Harel, and Dirk Schepmann, and Helge Prinz, and Reto Brun, and Thomas J Schmidt, and Bernhard Wünsch
March 2011, European journal of medicinal chemistry,
Dipak Harel, and Dirk Schepmann, and Helge Prinz, and Reto Brun, and Thomas J Schmidt, and Bernhard Wünsch
August 2021, Bioorganic chemistry,
Dipak Harel, and Dirk Schepmann, and Helge Prinz, and Reto Brun, and Thomas J Schmidt, and Bernhard Wünsch
August 2018, European journal of medicinal chemistry,
Dipak Harel, and Dirk Schepmann, and Helge Prinz, and Reto Brun, and Thomas J Schmidt, and Bernhard Wünsch
April 1985, Journal of medicinal chemistry,
Dipak Harel, and Dirk Schepmann, and Helge Prinz, and Reto Brun, and Thomas J Schmidt, and Bernhard Wünsch
May 2012, Bioorganic & medicinal chemistry,
Dipak Harel, and Dirk Schepmann, and Helge Prinz, and Reto Brun, and Thomas J Schmidt, and Bernhard Wünsch
June 2022, Bioorganic & medicinal chemistry letters,
Dipak Harel, and Dirk Schepmann, and Helge Prinz, and Reto Brun, and Thomas J Schmidt, and Bernhard Wünsch
May 2012, Bioorganic & medicinal chemistry letters,
Dipak Harel, and Dirk Schepmann, and Helge Prinz, and Reto Brun, and Thomas J Schmidt, and Bernhard Wünsch
May 2014, Bioorganic & medicinal chemistry letters,
Dipak Harel, and Dirk Schepmann, and Helge Prinz, and Reto Brun, and Thomas J Schmidt, and Bernhard Wünsch
May 2015, Organic & biomolecular chemistry,
Dipak Harel, and Dirk Schepmann, and Helge Prinz, and Reto Brun, and Thomas J Schmidt, and Bernhard Wünsch
February 2014, Molecules (Basel, Switzerland),
Copied contents to your clipboard!